PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation

Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges

(2017) Etienne Giroux Leprieur et al.   EUROPEAN JOURNAL OF CANCER

The next generation of immunotherapy: keeping lung cancer in check

(2017) Ashwin Somasundaram et al.   Journal of Hematology & Oncology

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

(2017) Toyoaki Hida et al.   LANCET

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy

(2017) Marianela Robainas et al.   OncoTargets and Therapy

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

(2016) Gautam Kishore Valecha et al.   Expert Review of Anticancer Therapy

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

(2016) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung cancer incidence and mortality in China, 2011

(2015) Rongshou Zheng et al.   Thoracic Cancer

EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3

(2015) Jaemoon Koh et al.   OncoImmunology

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

(2015) Shaodong Hong et al.   OncoImmunology

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Molecular Detection and Clinical Significance of ALK Rearrangement in Selected Advanced Non-Small Cell Lung Cancer: ALK Expression Provides Insights into ALK Targeted Therapy

(2014) Ning-Ning Zhang et al.   PLoS One

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

(2012) J Tanizaki et al.   BRITISH JOURNAL OF CANCER

Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung

(2012) Jennifer M. Boland et al.   Clinical Lung Cancer

Localization and Androgen Regulation of Metastasis-Associated Protein 1 in Mouse Epididymis

(2010) Li Ma et al.   PLoS One

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA